The estimated Net Worth of Xiaobin Wu is at least $30.5 Million dollars as of 1 May 2019. Dr Wu owns over 5,955 units of BeiGene Ltd stock worth over $3,666,620 and over the last 7 years he sold BGNE stock worth over $25,604,663. In addition, he makes $1,225,407 as Pres und COO & GM of China at BeiGene Ltd.
Dr has made over 25 trades of the BeiGene Ltd stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 5,556 units of BGNE stock worth $1,053,695 on 3 September 2024.
The largest trade he's ever made was selling 10,180 units of BeiGene Ltd stock on 6 July 2021 worth over $3,313,895. On average, Dr trades about 3,412 units every 63 days since 2018. As of 1 May 2019 he still owns at least 17,365 units of BeiGene Ltd stock.
You can see the complete history of Dr Wu stock trades at the bottom of the page.
Dr. Xiaobin Wu Ph.D. is the Pres, COO & GM of China at BeiGene Ltd.
As the Pres und COO & GM of China of BeiGene Ltd, the total compensation of Dr D at BeiGene Ltd is $1,225,407. There are 4 executives at BeiGene Ltd getting paid more, with John Oyler having the highest compensation of $13,899,000.
Dr D is 59, he's been the Pres und COO & GM of China of BeiGene Ltd since . There are 5 older and 16 younger executives at BeiGene Ltd. The oldest executive at BeiGene Ltd is Donald Glazer, 75, who is the Non-Executive Independent Director.
Xiaobin's mailing address filed with the SEC is C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN, E9, KY1-1108.
Over the last 9 years, insiders at BeiGene Ltd have traded over $1,899,158,980 worth of BeiGene Ltd stock and bought 23,241,738 units worth $1,040,248,444 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Investment Management, Ltd.... und Bros. Advisors Lp Baker Bro.... On average, BeiGene Ltd executives and independent directors trade stock every 13 days with the average trade being worth of $33,382,815. The most recent stock trade was executed by Xiaobin Wu on 3 September 2024, trading 5,556 units of BGNE stock currently worth $1,053,695.
BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib.
BeiGene Ltd executives and other stock owners filed with the SEC include: